Teledyne sales dip but profits up for third quarter
Thousand Oaks-based industrial conglomerate Teledyne Technologies saw sales dip but profits increase during the third quarter, according to figures released Nov. 3. Revenues for the company dipped to $526.8 million in the third quarter, compared to $551.7 during the third quarter of 2015. That missed analyst revenue estimates of $553 million, according to S&P Capital Read More →
Read More →Amgen beats analysts’ revenue, earnings per share estimates
Amgen revenues increased 2 percent during the third quarter as it beat analysts’ revenue and earnings per share estimates thanks to cost-cutting measures and lower research measures. Revenues for the Thousand Oaks-based biotech giant increased from $5.72 billion during the third quarter of 2015 to $5.81 billion in 2016, which beat analyst estimates of $5.73 Read More →
Read More →Proposition 61 will not cure sky high drug prices
Proposition 61 goes before California voters in just a few weeks. And as the Business Times reported on Oct. 14, Amgen, the Thousand Oaks-based biotech giant, along with other major drug companies, is spending millions to oppose Proposition 61 and its plan to control drug prices. Proponents promote the David vs. Goliath aspect of their Read More →
Read More →Being in charge of a company does not make you a leader
By Ritch K. Eich It’s been a bad year for some top business, media and political leaders. Roger Ailes, the founder, former chairman and CEO of Fox News, was ousted after numerous complaints of sexual harassment surfaced. Rep. Debbie Wasserman Schultz resigned as head of the Democratic National Committee after a leak exposed efforts to Read More →
Read More →Amgen to pay $1 quarterly dividend
Thousand Oaks-based biotech giant Amgen announced another quarterly dividend of $1 per share Oct. 14 for the fourth quarter of 2016. The dividend will be paid on Dec. 8, 2016, to all stockholders of record as of the close of business on Nov. 16, 2016. • Contact Philip Joens at pjoens@pacbiztimes.com.
Read More →